News

GEN - Genetic Engineering and Biotechnology News3h
Cutting CAR T Costs via Decentralization, Vector-Alternatives, and Artificial Intelligence
T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.
isixsigma on MSN4h
From Waterfall to Scrum: How to Navigate the Transition Smoothly
Key Points The transition from Waterfall to Scrum should take place gradually, using planned phases to implement the ...
Le Lézard7h
CDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager Platform
CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with ...